Radiopharmaceutical compositions for actinium in targeted radionuclide therapy
AssigneeCurium US LLC
InventorsJarno Jalomäki, Salla Seppänen, Riku Parviainen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.
Claims26
A composition comprising 225Ac-PSMA I&T, wherein the molar ratio of the PSMA I&T to 225Ac is from ≥50:1.0, ≥100:1.0, ≥500:1.0, ≥1,000:1.0, ≥2,000:1.0, ≥3,000:1.0, or ≥4,000:1.0, and the composition is suitable for administration to a human patient in need thereof.
A composition comprising 225Ac-PSMA I&T, wherein the molar ratio of the PSMA I&T to 225Ac is from 1,000:1.0 to 5,000:1.0, 2,000:1.0 to 4,000:1.0, or 2,500:1.0 to 3,500:1.0, and the composition is suitable for administration to a human patient in need thereof.
Dependencies are inferred from the claim text.